Concurrent versus sequential chemoradiotherapy for unresectable locally advanced stage III non-small cell lung cancer: Retrospective analysis in a single United Kingdom cancer centre-Reference-Cited by-同舟云学术

Concurrent versus sequential chemoradiotherapy for unresectable locally advanced stage III non-small cell lung cancer: Retrospective analysis in a single United Kingdom cancer centre

Published:2021 Issue: Volume:29 Page:100460
ISSN:2468-2942
Container-title:Cancer Treatment and Research Communications
language:en
Short-container-title:Cancer Treatment and Research Communications

Author:

Spencer Alice,Williams Jenna,Samuel Robert,Boon Ian S.,Clarke Katy,Jain Pooja

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference39 articles.

1. Cancer Registration Statistics,2019

2. Cancer Research UK. Lung Cancer Survival Statistics [Internet]. 2018 [cited 2018 Oct 24]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/survival.

3. Stereotactic ablative radiotherapy (SABR) in patients with medically inoperable peripheral early stage lung cancer: outcomes for the first UK SABR cohort;Murray;Clinical Oncol. [Internet].,2016

4. The international association for the study of lung cancer lung cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the tnm classification for lung cancer;Nicholson;J. Thoracic Oncol.,2016

5. The current treatment landscape in the UK for stage III NSCLC;Evison;Br. J. Cancer [Internet],2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Establishment of a prognostic nomogram for elderly patients with limited-stage small cell lung cancer receiving radiotherapy;Scientific Reports;2024-05-25

2. Pneumonitis with combined immune checkpoint inhibitors and chemoradiotherapy in locally advanced non-small-cell lung cancer: a systematic review and meta-analysis;Future Oncology;2023-05

3. Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?;Therapeutic Advances in Medical Oncology;2022-01